Alzamend Neuro, Inc. — Form 10-Q Summary
Business context and reporting period. This unaudited quarterly report covers the fiscal quarter and six months ended October 31, 2022. Alzamend is an early clinical-stage biopharmaceutical company developing AL001, a lithium-based drug candidate, and ALZN002, a cell-based therapeutic vaccine candidate, for Alzheimer’s and other indications. It has not generated product revenue and expects losses to continue.
Financial performance and position
| Metric | Three months ended Oct. 31, 2022 | Six months ended Oct. 31, 2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $1.53 million | $2.91 million |
| General and administrative expense | $1.57 million | $3.23 million |
| Net loss | $3.11 million | $6.15 million |
| Basic and diluted loss per share | $0.03 | $0.06 |
| Net cash used in operating activities | Not presented for quarter | $4.88 million |
At October 31, cash was $9.18 million, current assets were $10.33 million, current liabilities were $1.64 million, total assets were $10.42 million, and stockholders’ equity was $8.79 million. The filing reports no cash equivalents. It does not report outstanding borrowings at period end; interest expense was $5,120 for the six months, primarily related to D&O insurance financing. The $14.88 million related-party note receivable for common stock is recorded as a reduction of equity, not as cash or a conventional debt liability.
Changes versus the prior comparable period
- Quarterly operating expenses fell 13% to $3.11 million, and quarterly net loss narrowed 14% to $3.11 million. R&D declined 12%; G&A declined 14%, largely reflecting lower stock-based compensation and professional fees.
- For the six months, operating expenses rose 4% to $6.14 million and net loss increased 4% to $6.15 million. R&D rose 9%, principally because scientific and clinical professional fees increased; G&A was broadly flat.
- Six-month operating cash use increased from $3.27 million to $4.88 million. There were no financing proceeds in the 2022 period, compared with $14.91 million of financing cash inflows in the 2021 period, mainly from the IPO.
- Cash decreased $4.88 million from April 30, 2022, to $9.18 million. The six-month loss per share improved to $0.06 from $0.07, while weighted-average shares increased to 97.49 million from 88.15 million.
Outlook, developments, and risks
- Management says October 31 cash is expected to meet anticipated cash requirements for the 12 months after issuance of the financial statements. It also says additional capital will be needed to fund development and ongoing operations; inability to raise capital could delay, reduce, or eliminate programs.
- AL001’s Phase I study data indicated dose-adjusted relative bioavailability comparable to marketed lithium carbonate at the tested dose, with reported tolerability and safety findings. A Phase IIA multiple-ascending-dose study in Alzheimer’s patients was underway; a healthy-adult cohort was added in October 2022. The company expects to pursue INDs for bipolar disorder, major depressive disorder, and PTSD after the current study.
- The FDA issued a “study may proceed” letter for ALZN002 on October 31, 2022. Management expected first patient dosing in the first quarter of 2023. The proposed Phase I/IIA study is intended to assess safety, tolerability, and efficacy and identify a dose for later study.
- Clinical development, regulatory approval, trial enrollment and costs, manufacturing, and future financing are key uncertainties. License agreements carry royalties and milestone payments, including substantial payments tied to later-stage development and regulatory or commercial milestones; failure to meet specified milestones may allow the licensor to terminate a license.
- Management reported ineffective internal control over financial reporting due to unremediated material weaknesses in accounting resources and review controls, as well as user-access and IT change-management controls. Remediation efforts were ongoing. The company stated that the financial statements fairly present its results notwithstanding these weaknesses.
- Related-party items include a $14.88 million ALSF note receivable secured by pledged shares, extended to December 31, 2023, and a BitNile marketing and brand-development agreement valued at $1.4 million. In November 2022, the company elected to pay the marketing fee with 933,334 shares; this occurred after quarter end.
Most important facts for investors to verify
- Whether cash and the stated 12-month runway remain adequate given operating cash use and the timing and cost of planned trials.
- Actual enrollment, timing, results, and regulatory progress for the AL001 and ALZN002 studies, including whether ALZN002 first dosing occurred as anticipated.
- Potential dilution: the filing lists 10.15 million warrants and 17.16 million stock options, and reports 96,427,624 common shares outstanding as of December 12, 2022.
- The status and collectability/terms of the related-party note receivable, related-party balances, and share-based payment for the BitNile agreement.
- Progress in remediating the disclosed material weaknesses and any subsequent changes in controls or reported financial information.
- Upcoming license royalties and milestone obligations, and whether any future funding or additional investment under the related-party financing arrangements is secured; the possible additional $10 million investment was not a committed cash balance.